Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) has recently announced that it has received written notice of compliance from the Listing Qualifications Staff of The Nasdaq Stock Market LLC. The notice indicated that for 12 consecutive trading days, from November 26, 2024, to December 12, 2024, the closing bid price of Citius Pharmaceuticals’ common stock has been $1.00 per share or greater. As a result, the company has regained compliance with Nasdaq Listing Rule 5550(a)(2).

In response to the compliance notice, Nasdaq has informed Citius Pharmaceuticals that it considers the matter closed, signifying a positive development for the company. This achievement underscores Citius Pharmaceuticals’ commitment to meeting and maintaining Nasdaq’s listing requirements.

Leonard Mazur, the Chairman and Chief Executive Officer of Citius Pharmaceuticals, signed the report on December 20, 2024, indicating the company’s adherence to the Securities Exchange Act of 1934. This regulatory development reflects a significant milestone for Citius Pharmaceuticals and its shareholders.

The information in this report highlights Citius Pharmaceuticals’ continued efforts to uphold regulatory standards and ensure compliance with exchange regulations, supporting the company’s position in the market.

(END OF ARTICLE)

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Citius Pharmaceuticals’s 8K filing here.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.